Diamedica Inc.

Monthly archive

Press Releases - 2008

DiaMedica Selected as one of Canada’s Top Ten™ Competition Winners for the Second Consecutive Year

Posted by admin on Sep, 30 2008

 WINNIPEG, Manitoba – Sept 30, 2008 – DiaMedica Inc.

DiaMedica Enrolls First Patient in Phase IIa Clinical Trial for DM-99

Posted by admin on Aug, 11 2008

 WINNIPEG, Manitoba – August 11, 2008 – DiaMedica Inc. (TSX-V:DMA), a drug discovery and clinical development company focused on a novel approach to treating type 2 diabetes, today announces enrollment of the first patient in the phase II proof of concept clinical trial with DM-99, the Company’s third drug candidate to enter phase II human trials.

DiaMedica Closes $1.8 Million Financing

Posted by admin on Aug, 7 2008

 THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

DiaMedica to Deliver Poster Presentation at World Conference on Clinical Pharmacology and Therapeutics

Posted by admin on Jul, 30 2008

 WINNIPEG, Manitoba – July 30, 2008 – DiaMedica Inc. (TSX-V:DMA), a drug discovery and development company focused on novel treatments for Type 2 diabetes, announces that it will be presenting results of a study at the 9th World Conference on Clinical Pharmacology and Therapeutics (www.cpt2008.org) in Quebec City, Canada today.

DiaMedica Meets Primary Endpoint from Phase II DM-83 Study in Type 2 Diabetes

Posted by admin on Jul, 14 2008

 WINNIPEG, Manitoba – July 14, 2008 – DiaMedica Inc. (TSX-V:DMA) (“DiaMedica”), a drug discovery and development company focused on novel treatments for Type 2 diabetes, today announces top-line results of a Phase II trial showing that its investigational drug DM-83 met the primary endpoint by lowering peak insulin levels in diabetic patients.

DiaMedica is to raise approximately $2.0 million

Posted by admin on Jun, 25 2008

 WINNIPEG, Manitoba – June 24, 2008 – DiaMedica Inc.

DiaMedica Announces Last Patient Out for DM-83 phase II human clinical trial

Posted by admin on May, 26 2008

 WINNIPEG, Manitoba – May 26, 2008 – DiaMedica Inc. (TSX-V:DMA), a drug discovery and development company focused on novel treatments for Type 2 diabetes, today announces last patient out in the phase II proof of concept clinical trial of DM-83.

DiaMedica Receives pre-IND FDA Guidance on DM-71

Posted by admin on May, 14 2008

 WINNIPEG, Manitoba – May 14, 2008 – DiaMedica Inc. (TSX-V:DMA), a drug discovery and development company focused on novel treatments for Type 2 diabetes, today announced that it has received feedback from the U.S. Food and Drug and Administration (FDA) on its pre-IND filing for DM-71, the Company’s lead compound.

DiaMedica Completes Enrollment in Phase II Clinical Trial for DM-83

Posted by admin on May, 8 2008

 WINNIPEG, Manitoba – May 5, 2008 – DiaMedica Inc. (TSX-V:DMA), a drug discovery and development company focused on novel treatments for Type 2 diabetes, today announces that it has enrolled the final patient in the phase II proof of concept clinical trial of DM-83.

DiaMedica Announces Changes to Board of Directors and Corporate Officers

Posted by admin on Apr, 8 2008

 Company Adds Experienced Pharmaceutical Executive Thomas Wellner to Board Rick Pauls Undertakes Additional Corporate Leadership

DiaMedica enrolls first patient in phase II human clinical trial for DM-83

Posted by admin on Mar, 18 2008

 WINNIPEG, Manitoba – March 18, 2008 - DiaMedica Inc. (TSX-V:DMA), a drug discovery and development company focused on novel treatments for type 2 diabetes, has announced that it enrolled  the first patient in the phase II proof of concept clinical trial of DM-83.

DiaMedica receives regulatory clearance for Phase II human study of DM-99

Posted by admin on Mar, 4 2008

 WINNIPEG, Manitoba – March 4, 2008 - DiaMedica Inc. (TSX-V:DMA), a drug discovery and development company focused on novel treatments for type 2 diabetes is pleased to announce that it has received regulatory clearance in the European Union to conduct a Phase II human study with DM-99 in type 2 diabetes patients.